Xcelience Strengthens Formulation Development Expertise With Key Hire

Xcelience Strengthens Formulation Development Expertise With Key Hire

Remains Steadfast to Vision of Quality, Expertise and Responsiveness

TAMPA, Fla.--(BUSINESS WIRE)--Xcelience, a leader in early drug development services, recently announced the addition of Brett F. Truitt, who will serve as Team Leader, Formulation Development in the Pharmaceutical Development Services division.

"The Xcelience culture is completely reliant on the quality of our people, and we are fortunate in our ability to both attract and retain top industry talent," stated CEO Derek Hennecke. "We hire as much for attitude as for scientific expertise and this key hire is representative of our commitment to remain a premier provider of formulation development services."

"Brett brings a strong scientific background in oral solid dosage form development, as well as an excellent service record of delivering high-quality project results in a timely manner," noted Paul Skultety, Director of Pharmaceutical Development Services. "We are fortunate to have found a candidate that excels in both scientific and client-facing arenas."

Truitt has over ten years experience in pharmaceutical research and formulation development. Prior to joining Xcelience, Mr. Truitt held various research and development positions at Bilcare Global Clinical Supplies (GCS), Shire Laboratories/Supernus Pharmaceuticals, Pfizer, Inc., and Procter and Gamble.

Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab.

About Xcelience: Keep on top of new developments in Xcelience and throughout the drug development industry by following us on Twitter www.twitter.com/Xcelience. For more detailed information about Xcelience, visit www.xcelience.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.